Angiocrine Bioscience, Inc.

Angiocrine Bioscience is a biotechnology firm specializing in engineered cellular therapies, particularly focusing on hematopoietic stem cell development to treat serious blood disorders and immune system conditions. Founded in 2012, Angiocrine Bioscience is located in San Diego, US, and focuses on developing therapies from hematopoietic stem cells. The company has undergone no major pivots and does not have any known subsidiaries. Angiocrine has successfully raised a total of USD 2.

1 mn in funding, with the latest round occurring on August 21, 2025. Angiocrine Bioscience specializes in innovative cellular therapies, focusing on hematopoietic stem cell-based products aimed at addressing serious blood disorders and immune system conditions. Their core offerings include proprietary technologies for expanding and differentiating stem cells, designed to enable more effective treatments for conditions such as leukemia and other hematological malignancies. The company targets a diverse client base that includes research institutions, hospitals, and biotechnology firms engaged in regenerative medicine, primarily marketing its products in North America and Europe.

Angiocrine Bioscience operates on a business model that emphasizes partnerships with healthcare providers and research institutions. Revenue is generated through collaborations, allowing clients to access Angiocrine’s proprietary technologies and cellular therapies under structured agreements. This includes licensing arrangements for the integration of Angiocrine's products into treatment protocols and direct collaborations for research and development. Specific pricing structures are tailored to client needs, reflecting the bespoke nature of the therapies offered.

Angiocrine’s flagship products are integral to these collaborative efforts. Looking ahead, Angiocrine Bioscience plans to leverage the USD 2. 1 mn raised in venture funding in August 2025 to support the development of new hematopoietic stem cell therapies. The company aims to expand its reach into new geographic markets in Europe and Asia by the end of 2026, targeting enhanced partnerships with healthcare institutions.

These initiatives are part of their strategy to establish a broader presence in the biotechnology sector and address rising global demand for innovative cellular therapies.